Kameda Tomohiro, Sugihara Toru, Obinata Daisuke, Oshima Masashi, Yamada Yuta, Kimura Naoki, Takayama Kenichi, Inoue Satoshi, Takahashi Satoru, Fujimura Tetsuya
Department of Urology, Jichi Medical University, 3311-1 Yakushiji Shimotsuke, Tochigi, 329-0498, Japan.
Department of Urology, Nihon University School of Medicine, Tokyo, Japan.
Sci Rep. 2024 Dec 28;14(1):30654. doi: 10.1038/s41598-024-74443-z.
This study aimed to identify the predictive factors associated with the oncological outcomes of metastatic hormone-sensitive prostate cancer-related genes. A nomogram for predicting prostate cancer-specific survival (CSS) was constructed based on biopsy samples obtained from 103 patients with metastatic hormone-sensitive prostate cancer. We analyzed the association between clinical data and mRNA expression levels. The nomogram was externally validated in another cohort (n = 50) by using a concordance index. Based on the cutoff value, determined by a receiver operating characteristic analysis, longer CSS was observed in the high osteoglycin and androgen receptor expression level groups (> 1.133 and > 0.00; median CSS, 85.3 vs. 52.7 months, p = 0.045, and 69.1 vs. 32.1 months, p = 0.034, respectively), compared with that of the low expression level groups. The nomogram predicting CSS included hemoglobin (≥ 13.7 g/dL or < 13.7 g/dL), serum albumin (≥ 3.1 g/dL or < 3.1 g/dL), serum lactate dehydrogenase (≥ 222 IU/L or < 222 IU/L), total Japan Cancer of the Prostate Risk Assessment score, androgen receptor expression level, and osteoglycin expression level. The concordance indices for the internal and external validations were 0.664 and 0.798, respectively. In this study, a nomogram that integrated the expression levels of androgen receptors and osteoglycin to predict CSS in metastatic hormone-sensitive prostate cancer was established.
本研究旨在确定与转移性激素敏感性前列腺癌相关基因的肿瘤学结局相关的预测因素。基于从103例转移性激素敏感性前列腺癌患者获得的活检样本构建了预测前列腺癌特异性生存（CSS）的列线图。我们分析了临床数据与mRNA表达水平之间的关联。通过一致性指数在另一个队列（n = 50）中对列线图进行了外部验证。根据受试者工作特征分析确定的临界值，与低表达水平组相比，在高骨甘蛋白和雄激素受体表达水平组（> 1.133和> 0.00；CSS中位数分别为85.3个月对52.7个月，p = 0.045，以及69.1个月对32.1个月，p = 0.034）中观察到更长的CSS。预测CSS的列线图包括血红蛋白（≥13.7 g/dL或<13.7 g/dL）、血清白蛋白（≥3.1 g/dL或<3.1 g/dL）、血清乳酸脱氢酶（≥222 IU/L或<222 IU/L）、日本前列腺癌总风险评估评分、雄激素受体表达水平和骨甘蛋白表达水平。内部验证和外部验证的一致性指数分别为0.664和0.798。在本研究中，建立了一个整合雄激素受体和骨甘蛋白表达水平以预测转移性激素敏感性前列腺癌CSS的列线图。
